Orserdu (elacestrant) — United Healthcare
Breast cancer (advanced or metastatic, ER-positive, HER2-negative, ESR1-mutated)
Initial criteria
- Diagnosis of breast cancer
- Disease is advanced OR metastatic
- Disease is estrogen receptor (ER)-positive
- Disease is human epidermal growth factor receptor 2 (HER2)-negative
- Presence of an ESR1 gene mutation
- Patient is one of the following: postmenopausal woman OR male OR premenopausal woman treated with ovarian ablation/suppression
- Disease has progressed following at least one line of endocrine therapy
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Orserdu therapy
Approval duration
12 months